Biagio Ricciuti

49PUBLICATIONS
406CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Jul 15, 2026
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

|Jul 14, 2026
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

|Jun 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway.

|May 25, 2026
Gene mutant dosage is associated with prognosis and metastatic tropism in 60,000 clinical cancer samples.

|May 22, 2026
Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies.

|May 18, 2026
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

Pageof 9

Frequent Collaborators

26 joint publications

Mark Magdi Awad

23 joint publications

Joao Victor Alessi

15 joint publications

Alessandro Di Federico

11 joint publications

Lynette Sholl